CNTA
NEUTRALM&ACentessa Pharmaceuticals plc
This is the 2026-05-12 snapshot — the signals and analysis for CNTA as of this single trading day.
View full CNTA research hub →Analysis
Centessa Pharmaceuticals (CNTA) is operating purely as a merger arbitrage play following Eli Lilly's definitive agreement to acquire the company for $38.00 per share in cash plus a Contingent Value Right (CVR) worth up to $9.00 per share. The stock's current price of $39.61 reflects the firm $38.00 cash floor along with a ~$1.61 probability-weighted premium assigned to the CVR milestones. The exceptionally low realized volatility of 2.9% and trend-following signals like PERFECT_STACK and STEADY_CLIMB perfectly illustrate classic institutional arbitrage accumulation rather than directional beta. Supported by a RISK_ON macro regime, buyers are confidently holding the stock through the deal timeline, pricing in a smooth closure and optionality on the FDA-tied CVR.
Fired Signals
Key Takeaways
- M&AArbitrage:CNTAispinnedtoEliLilly'sbuyoutterms, tradingata~$1.61premiumtothe$38cashfloor, whichrepresentsthemarket'sassignedvaluetothe$9CVR[2.1].
- Deal Risk: The primary downside risk is regulatory or shareholder intervention that breaks the $38 base deal, though this is currently viewed as low probability.
- Next Hurdle: The shareholder vote on June 12, 2026, is the immediate catalyst to clear the path for a Q3 2026 closure.